Earnings call transcript: Alexandria RE Q1 2026 beats EPS expectations

Alexandria Real Estate Equities posted a major Q1 EPS beat of $2.10 versus $0.15 expected, but revenue missed at $671.0M versus $684.2M, and the stock fell 11.57% after hours to $44.90. Management reaffirmed full-year 2026 FFO guidance at a $6.40 midpoint, but trimmed Q4 2026 FFO guidance to a $1.45 midpoint and lowered year-end occupancy guidance to 87.0% from 88.5%. The call highlighted ongoing leasing कमजोरी in public biotech, softer same-property NOI, and a shift toward alternative/advanced technology uses and JVs to support capital recycling.

Analysis

ARE’s print is less about a one-quarter earnings beat and more about a re-pricing of the duration of the downcycle. The market is signaling that “quality platform” no longer earns a premium multiple when occupancy is falling and the path to stabilization is pushed into late 2026; in that regime, a strong balance sheet becomes a defensive attribute, not a growth catalyst. The second-order beneficiary is anything that can absorb mission-critical space with lower capex intensity — especially flexible technical/industrial users — because landlords will increasingly underwrite to faster revenue conversion rather than lab purity.

The biggest hidden issue is not the 2026 guide, but the increasing probability that 2027 becomes a rollover year unless leasing accelerates materially into Q2/Q3. That creates a valuation overhang because investors will start capitalizing near-term vacancy risk rather than normalized FFO, which can keep the stock cheap even if reported cash flow holds up. The fact that capital recycling is shifting toward JVs and alternative-use monetization tells you the market for core life science assets is still open, but only at a price that transfers more upside to new capital providers.

Contrarian view: the selloff may be overdone if one believes capital markets for innovative medicine bottom before occupancy does. Public biotech leasing being absent for a quarter is dramatic, but the more important signal is that management is actively reconfiguring asset use rather than forcing bad lab economics; that can actually reduce future capex and shorten the time to NOI. If 311 Arsenal / 3,000 Minuteman convert successfully, the market may be underestimating how much of ARE’s portfolio can be repurposed without destroying franchise value.

Key Decisions for Investors

• Short ARE into any strength over the next 2-6 weeks; risk/reward favors another leg down if leasing momentum does not improve before the next occupancy update. Use a tight stop above the post-earnings gap-fill area; downside is driven by multiple compression, not just FFO.
• Pair trade: long NVS / short ARE for 1-3 months. NVS benefits if biotech funding normalizes while ARE remains exposed to delayed real-estate demand; this isolates the tenant-demand recovery trade from property-level execution risk.
• Consider a call spread financed by stock sale hedges only after evidence of Q2 leasing acceleration; until then, upside is capped by 2027 downtime risk. Best entry would be after a failed bounce, not immediately post-print.
• If seeking relative-value exposure to alternative-use conversion, prefer LDOS or AMZN over ARE as a cleaner way to express technical-space demand without balance-sheet and vacancy overhang. Time horizon: 3-9 months.
• Monitor for a tactical long only if occupancy guidance stabilizes and the company closes additional JVs/dispositions faster than expected; then a mean-reversion trade could work with 15-20% upside, but not before.